Adrixetinib TFA

Adrixetinib (TFA) is a small molecule tyrosine kinase inhibitor with antineoplastic activity, primarily targeting receptors such as MET and VEGFR2. It is applied in oncology research for studying tumor growth and angiogenesis, utilizing both in vitro kinase assays and in vivo xenograft models.